HC Wainwright Has Pessimistic Outlook of Absci Q3 Earnings

Key Points

• HC Wainwright has lowered their Q3 2025 EPS estimate for Absci Corporation from ($0.06) to ($0.20), reflecting a negative outlook for the company's earnings.
• Absci's stock has seen a recent downgrade from various analysts, with Needham reducing its target price from $9.00 to $8.00, while Morgan Stanley also cut their target to $6.40.
• Insider Andreas Busch purchased 50,000 shares of Absci, indicating confidence in the stock despite its current challenges.

Absci Corporation (NASDAQ:ABSI - Free Report) - Analysts at HC Wainwright cut their Q3 2025 earnings per share (EPS) estimates for Absci in a note issued to investors on Wednesday, August 13th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.20) per share for the quarter, down from their prior forecast of ($0.06). The consensus estimate for Absci's current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Absci's Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.85) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.47) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at $0.22 EPS and FY2029 earnings at $0.19 EPS.

Absci (NASDAQ:ABSI - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.05). Absci had a negative return on equity of 60.21% and a negative net margin of 2,737.94%.The firm had revenue of $0.59 million during the quarter, compared to analyst estimates of $1.39 million.

A number of other brokerages have also recently weighed in on ABSI. Morgan Stanley reduced their price target on Absci from $6.40 to $5.89 and set an "overweight" rating for the company in a research report on Monday. Needham & Company LLC lowered their price target on Absci from $9.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, August 13th. Finally, Wall Street Zen cut shares of Absci from a "hold" rating to a "strong sell" rating in a research note on Saturday. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $7.98.

Absci Price Performance

ABSI traded down $0.21 during trading on Friday, reaching $2.62. 6,984,179 shares of the stock traded hands, compared to its average volume of 6,489,728. The stock has a market cap of $391.74 million, a price-to-earnings ratio of -2.79 and a beta of 2.02. Absci has a fifty-two week low of $2.01 and a fifty-two week high of $6.33. The stock's 50-day simple moving average is $2.87 and its two-hundred day simple moving average is $3.14.

Institutional Trading of Absci

Several hedge funds have recently added to or reduced their stakes in ABSI. Cambridge Investment Research Advisors Inc. acquired a new stake in shares of Absci during the 1st quarter worth approximately $26,000. Neuberger Berman Group LLC acquired a new position in shares of Absci during the 1st quarter worth $26,000. BNP Paribas Financial Markets bought a new stake in shares of Absci during the 4th quarter worth $28,000. AssuredPartners Investment Advisors LLC acquired a new stake in Absci in the first quarter valued at about $29,000. Finally, Legal & General Group Plc grew its position in Absci by 45.9% in the second quarter. Legal & General Group Plc now owns 11,690 shares of the company's stock valued at $30,000 after acquiring an additional 3,678 shares during the last quarter. 52.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Absci

In other news, insider Andreas Busch bought 50,000 shares of the business's stock in a transaction on Monday, July 28th. The shares were bought at an average cost of $3.04 per share, for a total transaction of $152,000.00. Following the completion of the acquisition, the insider owned 327,264 shares in the company, valued at approximately $994,882.56. This trade represents a 18.03% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.49% of the company's stock.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.